Re-Pharm Identifies Novel Anti-Inflammatory Activity for Existing Compound
News Feb 11, 2015
Re-Pharm has announced the identification of RP0217 as an effective new anti-inflammatory agent.
RP0217 is an existing drug which is widely prescribed for non-inflammatory conditions. The identification of this novel anti-inflammatory activity creates the opportunity to develop new non-steroidal approaches to the treatment of a variety of disease indications.
“Re-Pharm is dedicated to re-purposing compounds to address areas of unmet medical need,” says Dr Alan Rothaul, CSO at Re-Pharm. “Our streamlined method made it possible to move efficiently through pharmacological assessment, computational chemistry work and initial testing in order to demonstrate novel anti-inflammatory activity for an existing drug.”
“We are delighted with the discovery of RP0217 and look forward to its progression through clinical trials,” says Dr Robert Scoffin, CEO at Re-Pharm. “The filing of our first patents represents a significant validation of Re-Pharm’s approach to re-profiling and I look forward to many similar future successes.”
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE
Discovery Provides Hope for New Vaccine Against Flesh-eating BacteriaNews
Researchers at Houston Methodist have solved a 100-year-old mystery, providing them a possible key to unlock a pathway for treating diseases caused by flesh-eating bacteria.READ MORE